Skip to main content
Premium Trial:

Request an Annual Quote

Mark Stevenson, Philip Chase, Eric Raichle, Jason Rhodes, Pauline Ryan, Ira Marks, Patricia Walicke, Peter Harris, Stephen Donahue

Premium
Applied Bioystems has promoted Mark Stevenson from president of the Molecular and Cell Division to executive vice president of the company. ABI said the Molecular and Cell Division will also be split into two groups: MCB Systems and MCB Consumables.
 

 
Alnylam has named Philip Chase to be vice president of legal affairs, Eric Raichle vice president of human resources, and Jason Rhodes vice president of business development.
 

 
ImmunoGen announced last week that Senior Vice President of Corporate Development and Operations Pauline Ryan has resigned from the company to pursue other interests. ImmunoGen is searching for a replacement for Ryan. In the transition period, day-to-day responsibilities will be handled by other members of ImmunoGen’s senior management team, the company said. 
 

 
Prodesse announced this week that it has elected Ira Marks to its board of directors. With more than 30 years of diagnostic and pharmaceutical industry experience, Marks held various positions with Bio-Rad, Nanogen, and Cepheid. He is currently general manager of MiltenyiBiotec.
 

 
OxiGene has named Patricia Walicke as its new chief medical officer and vice president. Walicke will replace Peter Harris, the company’s current chief medical officer. Walicke comes to OxiGene from the Amgen subsidiary Avidia, where she was vice president of clinical and regulatory affairs. Walicke has also held various posts in Rinat Neurosciences, Genentech, and Quintiles.
 

 
Gene Logic announced this week that Stephen Donahue will be its senior vice president of clinical development. Donahue will lead the Gene Logic’s clinical development efforts for its drug repositioning business. Donahue was previously vice president of clinical research and operations at Epix Pharmaceutical. He has also held positions at Merck and Bristol-Myers Squibb.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.